E 系列 18(S)- resolvins 的生物合成
中文名称
通路描述
鱼油中主要的 Ï-3 多不饱和脂肪酸（PUFA）Eicosapentaenoic acid（EPA）是 E 系列 resolvins 的来源，后者是一类具有强大抗炎和促恢复作用的特化抗炎介质（SPMs）。EPA 的初始转化可由细胞色素 P450 和/或阿司匹林乙酰化的环氧化酶 -2 介导，从而产生立体特异性的 18(R)-和 18(S)-E-resolvins。氧化、还原和水解反应的组合决定了形成的 E-resolvins 的类型（RvE1、RvE2 或 RvE3）。阿司匹林乙酰化环氧化酶异构体会导致酶活性改变。环氧化酶 -1 的乙酰化导致其抑制，从而阻止炎症介质的产生。然而，环氧化酶 -2 的乙酰化将其酶活性从环氧化酶转变为脂氧合酶，从而阻断前列腺素生物合成，并额外启动 SPMs 的产生（Arita et al. 2005, Kyriakopoulos et al. 2017）。本文描述了 18(S) E-resolvins 的生物合成。
英文描述
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB Human monoamine oxidases (MAOs) are flavin-containing enzymes that are present on the outer mitochondrial membrane and act on primary, secondary and tertiary amines. In contrast to the P450s which have a large number of isozymes, MAOs number only two isozymes, MAO-A and MAO-B. These gene products share over 70% sequence identity, are approximately 59KDa in size and have overlapping substrates (for example dopamine, tryamine and tryptamine) but each form also has distinct substrate specificities. MAO-A (primary type in fibroblasts) preferentially oxidises serotonin (5-Hydroxytryptamine) whereas MAO-B (primary type in platelets) prefers phenylethylamine. MAOs are of particular clinical interest because of the use of MAO inhibitors (MAOI) as antidepressants or in the treatment of neurodegenerative diseases Benedetti 2001, Beedham 1997).
所含基因
2 个基因